LIMBITROL DS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIMBITROL DS (LIMBITROL DS).
Limbitrol DS is a combination of amitriptyline (a tricyclic antidepressant) and chlordiazepoxide (a benzodiazepine). Amitriptyline inhibits the reuptake of serotonin and norepinephrine, enhancing neurotransmission in the CNS. Chlordiazepoxide binds to GABA-A receptors, potentiating GABAergic inhibitory effects, leading to anxiolytic and sedative effects.
| Metabolism | Amitriptyline is primarily metabolized by CYP2C19, CYP2D6, and CYP3A4 to nortriptyline and other metabolites. Chlordiazepoxide is metabolized by CYP3A4 and other enzymes to active metabolites such as desmethylchlordiazepoxide and demoxepam. |
| Excretion | Renal: 70-80% as conjugated metabolites, <5% unchanged; fecal: 10-20% via biliary excretion. |
| Half-life | Chlordiazepoxide: 5-30 hours (parent drug), active metabolite (desmethylchlordiazepoxide) 10-30 hours; amitriptyline: 13-36 hours (parent), nortriptyline (active metabolite) 18-44 hours. Half-lives increase with age and hepatic impairment. |
| Protein binding | Chlordiazepoxide: 90-98% (albumin); amitriptyline: 82-96% (albumin, alpha-1-acid glycoprotein). |
| Volume of Distribution | Chlordiazepoxide: 0.3-2.0 L/kg (large distribution, extensive tissue binding); amitriptyline: 10-20 L/kg (very large, high tissue affinity). |
| Bioavailability | Oral: Chlordiazepoxide 100%; amitriptyline 30-60% (first-pass metabolism). |
| Onset of Action | Oral: Chlordiazepoxide 30-60 min; amitriptyline 2-4 hours (antidepressant effect may take 2-4 weeks). |
| Duration of Action | Oral: Chlordiazepoxide 8-24 hours; amitriptyline 24-48 hours. Clinical antidepressant effect requires daily dosing for weeks. |
1 tablet (amitriptyline 25 mg/chlordiazepoxide 10 mg) orally 3 times daily initially, gradually increasing to 2 tablets orally 3 times daily or 3 tablets orally twice daily if needed; maximum 6 tablets per day.
| Dosage form | TABLET |
| Renal impairment | Use with caution; no specific dose adjustments defined. For GFR 15-29 mL/min: consider 50% dose reduction. For GFR <15 mL/min: avoid use due to potential accumulation of both components. |
| Liver impairment | Child-Pugh Class A: no adjustment recommended. Child-Pugh Class B: reduce dose by 50% (e.g., 1 tablet twice daily). Child-Pugh Class C: contraindicated. |
| Pediatric use | Not recommended for use in children under 12 years due to lack of safety and efficacy data. For adolescents >12 years: use adult doses with caution; initial 1 tablet (25/10 mg) 2-3 times daily, titrate slowly. |
| Geriatric use | Initiate at lower dose (e.g., 1 tablet (25/10 mg) 1-2 times daily) due to increased sensitivity to anticholinergic and sedative effects; titrate slowly. Maximum recommended dose: 2 tablets per day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LIMBITROL DS (LIMBITROL DS).
| Breastfeeding | Both components are excreted into breast milk. Amitriptyline M/P ratio approximately 1.0-1.5; chlordiazepoxide M/P ratio unknown. Low levels detected in infant serum. American Academy of Pediatrics considers amitriptyline usually compatible with breastfeeding, but chlordiazepoxide may cause sedation. Use only if benefit outweighs risk; monitor for drowsiness, poor feeding. |
| Teratogenic Risk | First trimester: Based on animal studies and limited human data, there is an increased risk of congenital malformations, particularly cardiovascular defects, with amitriptyline. Limb reduction anomalies reported with chlordiazepoxide. Second/third trimester: Chronic use may lead to neonatal withdrawal syndrome (irritability, hypertonia, tremors) and neonatal sedation (lethargy, poor feeding, respiratory depression). |
■ FDA Black Box Warning
WARNING: Suicidality and Antidepressant Drugs - Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders. Limbitrol DS is not approved for use in pediatric patients.
| Serious Effects |
["Hypersensitivity to amitriptyline, chlordiazepoxide, or any component","Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation","Acute recovery phase after myocardial infarction","Concurrent use of cisapride, certain antiarrhythmics, or other QT-prolonging drugs","Narrow-angle glaucoma (untreated)","Breastfeeding (due to benzodiazepine component)"]
| Precautions | ["Clinical worsening and suicide risk: Monitor for worsening depression, suicidal thoughts/behaviors, especially during initial therapy","Serotonin syndrome: Risk with concurrent serotonergic drugs","CNS depression: Additive effects with other CNS depressants, caution with hazardous activities","Cardiotoxicity: May prolong QT interval, caution in patients with cardiovascular disease","Tolerance and dependence: Benzodiazepine component may cause physical and psychological dependence; withdrawal symptoms upon discontinuation","Anticholinergic effects: Amitriptyline may cause dry mouth, blurred vision, urinary retention, constipation; use caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs, liver function, CBC. Fetal: serial ultrasounds for growth and anatomy; neonatal monitoring for withdrawal symptoms and sedation after delivery. |
| Fertility Effects | Amitriptyline may cause erectile dysfunction and ejaculatory disturbances; chlordiazepoxide may affect menstrual cycle and libido. Animal studies show no direct impairment of fertility. Clinical significance in humans unclear. |